Global Human Growth Hormone Market

Human Growth Hormone Market Size, Share, Growth Analysis, By Product(Long Acting, Others), By Application(Growth Hormone (GH) Deficiency (Adult GH Deficiency, Pediatric GH Deficiency), Turner Syndrome, Idiopathic Short Stature), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2308 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 68 | Figures: 75

Human Growth Hormone Market Competitive Landscape

The global human growth hormone market presents a hybrid competition between ‘old fashioned' big pharmaceuticals and ‘upstart' newcomers. Braun Medical, Inc., Genentech (a division of Roche), Pfizer, Merck KGaA and Novo Nordisk are amongst the key global players with a strong market share and innovation. These firms concentrate on novel recombinant methods and aggressive marketing to fortify their firms' positions. More factors of competition emerge with increased cooperation and formation of strategic alliances, in turn resulting in more progress made in HGH therapies. 

Top Players in Human Growth Hormone Market

  • Novo Nordisk A/S  
  • Pfizer, Inc 
  • Eli Lilly and Company 
  • Sandoz International GmbH (Novartis AG) 
  • Merck KGaA 
  • Genentech , Inc (Roche) 
  • Ferring Pharmaceuticals 
  • Teva Pharmaceutical Industries, Ltd 
  • Ipsen 
  • GeneScience Pharmaceuticals 
  • LG Chem 
  • Anhui Anke Biotechnology Group 
  • Biopartners 
  • Endo International 
  • Versartis 
  • Opko Health 
  • Rani Therapeutics 
  • Somatopac 
  • Hua'an Biological 
  • Hangzhou Just Biotech 
  • Shenzhen Hybio Pharmaceutical

Human Growth Hormone Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Human Growth Hormone Market size was valued at USD 6.32 Billion in 2023 and is poised to grow from USD 7.1 Billion in 2024 to USD 18.01 Billion by 2032, growing at a CAGR of 12.34% during the forecast period (2025-2032).

The global human growth hormone market presents a hybrid competition between ‘old fashioned’ big pharmaceuticals and ‘upstart’ newcomers. Braun Medical, Inc., Genentech (a division of Roche), Pfizer, Merck KGaA and Novo Nordisk are amongst the key global players with a strong market share and innovation. These firms concentrate on novel recombinant methods and aggressive marketing to fortify their firms’ positions. More factors of competition emerge with increased cooperation and formation of strategic alliances, in turn resulting in more progress made in HGH therapies.  'Novo Nordisk A/S  ', 'Pfizer, Inc ', 'Eli Lilly and Company ', 'Sandoz International GmbH (Novartis AG) ', 'Merck KGaA ', 'Genentech , Inc (Roche) ', 'Ferring Pharmaceuticals ', 'Teva Pharmaceutical Industries, Ltd ', 'Ipsen ', 'GeneScience Pharmaceuticals ', 'LG Chem ', 'Anhui Anke Biotechnology Group ', 'Biopartners ', 'Endo International ', 'Versartis ', 'Opko Health ', 'Rani Therapeutics ', 'Somatopac ', 'Hua'an Biological ', 'Hangzhou Just Biotech ', 'Shenzhen Hybio Pharmaceutical'

The growing prevalence of aberrations in growth patterns such as Turner syndrome and growth hormone deficiency, has been the primary factor affecting the demand for human growth hormone products globally. With increased knowledge, there is increased diagnosis at early stages leading to further increasing demand for high therapies. This proclivity, together with enhanced accessibility of health care, drives global human growth hormone market growth. 

Rising Demand for Personalized Treatment Approaches: The global human growth hormone market is on a trend of moving towards more personalized treatment approaches in particular dosing and delivery techniques. Progress in biotechnology means that healthcare professionals can now offer individualized growth hormone therapies which improve results as well as the patient’s experience. 

North America leads the global human growth hormone market due to advanced healthcare infrastructure, high awareness, and extensive research and development initiatives. The region enjoys favorable regulations and high healthcare expenditure, which allows for early detection and access to HGH therapies. The concentration of pharmaceutical companies and the relentless advances in the methods of dispensing drugs also help consolidate North America’s market leadership. Moreover, the increasing number of growth disorders, and the willingness to explore new treatment options, fuels growth. The region’s propensity to develop therapies that place the patient at the center and the highly sophisticated medical equipment available in the region also serve to explain why North America still leads the HGH market. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Human Growth Hormone Market

Report ID: SQMIG35I2308

$5,300
BUY NOW GET FREE SAMPLE